Skip to the content
pharmaceutical daily

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Study shows IONA test can predict the presence of Down’s, Edward’s, and Patau’s syndrome
November 12, 2015 Off

Study shows IONA test can predict the presence of Down’s, Edward’s, and Patau’s syndrome

By Dino Mustafić

Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.

Horizon Pharma about Express Scripts’ business practices
November 11, 2015 Off

Horizon Pharma about Express Scripts’ business practices

By Dino Mustafić

Horizon Pharma about Express Scripts’ business practices: “Express Scripts… also operates its own mail-order pharmacy and thus is a direct competitor of small, independent specialty pharmacies”

Horizon Pharma and ALR will together study RAYOS
November 11, 2015 Off

Horizon Pharma and ALR will together study RAYOS

By Dino Mustafić

Horizon Pharma on Wednesday announced a collaboration with the Alliance for Lupus Research (ALR) to study RAYOS (prednisone) delayed-release tablets in systemic lupus erythematosus (SLE).

Anavex confirms positive efficacy Phase2 Alzheimer’s trial for its Anavex 2-73 datahad
November 11, 2015 Off

Anavex confirms positive efficacy Phase2 Alzheimer’s trial for its Anavex 2-73 datahad

By Dino Mustafić

Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

4D pharma gets OK for clinical trial of Thetanix
November 11, 2015 Off

4D pharma gets OK for clinical trial of Thetanix

By Dino Mustafić

4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.

Biofrontera’s business not affected by ongoing approval processes
November 11, 2015 Off

Biofrontera’s business not affected by ongoing approval processes

By Dino Mustafić

Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.

Plavix does not affect overall risk of death in patients with heart disease.
November 11, 2015 Off

Plavix does not affect overall risk of death in patients with heart disease.

By Dino Mustafić

Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.

Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”
November 11, 2015 Off

Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”

By Dino Mustafić

Diplomat Pharmacy, NYSE-listed pharmaceutical company, will dispense Cotellic in combination with the BRAF inhibitor Zelboraf to treat patients with advanced melanoma that cannot be removed by surgery, or that has spread from the primary site.

November 11, 2015 Off

Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents

By Dino Mustafić

Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents.

Allergan submits Prior Approval Supplement for RESTASIS
November 11, 2015 Off

Allergan submits Prior Approval Supplement for RESTASIS

By Dino Mustafić

Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.

Posts navigation

Previous 1 … 2,582 2,583 2,584 … 2,602 Next

Popular posts

NOXXON Successfully Completes Patient Recruitment in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy

April 14, 2021 Off

Novartis: Long -term disease control for polycythemia vera patients treated with Jakavi

June 15, 2015 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off
Proudly powered by WordPress | Theme: Envo Magazine